Anmelden Kostenlos registrieren

Akari Therapeutics Plc Geschätzer EPS Q/Q

Was ist das Geschätzer EPS Q/Q von Akari Therapeutics Plc?

Geschätzer EPS Q/Q von Akari Therapeutics Plc ist -100.00%

Was ist die Definition von Geschätzer EPS Q/Q?



Die voraussichtliche vierteljährliche EPS-Wachstumsrate im Jahresvergleich ist die geschätzte Steigerung des EPS eines Unternehmens für das nächste Quartal im Vergleich zur Leistung aus einem vergangenen entsprechenden Quartal.

The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

Geschätzer EPS Q/Q von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Akari Therapeutics Plc

Was macht Akari Therapeutics Plc?

akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.

Unternehmen mit geschätzer eps q/q ähnlich Akari Therapeutics Plc